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Aim: To estimate the potential cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK
setting.
Methods: Using data from a variety of sources a Markov model was built to produce estimates of the cost
effectiveness (incremental cost per quality adjusted life year (QALY) and incremental cost per vision year
gained) of PDT for two cohorts of patients (one with starting visual acuity (VA) of 20/40 and one at
20/100) with predominantly classic choroidal neovascular disease over a 2 year and 5 year time
horizon. A government perspective and a treatment cost only perspective were considered. Probabilistic
and one way sensitivity analyses were undertaken.
Results: From the government perspective, over the 2 year period, the expected incremental cost
effectiveness ratios range from £286 000 (starting VA 20/100) to £76 000 (starting VA 20/40) per
QALY gained and from £14 000 (20/100) to £34 000 (20/40) per vision year gained. A 5 year
perspective yields incremental ratios less than £5000 for vision years gained and from £9000 (20/40) to
£30 000 (20/100) for QALYs gained. Without societal or NHS cost offsets included, the 2 year
incremental cost per vision year gained ranges from £20 000 (20/100) to £40 000 (20/40), and the
2 year incremental cost per QALY gained ranges from £412 000 (20/100) to £90 000 (20/40). The
5 year time frame shows expected costs of £7000 (20/40) to £10 000 (20/100) per vision year gained
and from £38 000 (20/40) to £69 000 (20/100) per QALY gained.
Conclusion: This evaluation suggests that early treatment (that is, treating eyes at less severe stages of
disease) with PDT leads to increased efficiency. When considering only the cost of therapy, treating people
at lower levels of visual acuity would probably not be considered cost effective. However, a broad
perspective that incorporates other NHS treatment costs and social care costs suggests that over a long
period of time, PDT may yield reasonable value for money.
A
ge related macular degeneration (AMD) is the leading
cause of registered blindness in the United Kingdom,1
has prevalence of .7% in the elderly,2 and is the main
cause of severe and irreversible loss of vision in developed
countries,3 leading to quality of life decrements.4 The wet
form of AMD is characterised by choroidal neovascularisation
(CNV) and may lead to acute visual loss.
Until recently, the only available treatment for wet AMD
was laser photocoagulation, but in the case of those with
subfoveal lesions (about 50%), it leads to immediate loss of
vision.3
This study examined the cost effectiveness in the United
Kingdom of photodynamic therapy (PDT) with verteporfin, a
treatment shown to slow the vision loss associated with
subfoveal CNV.5 Unlike previous analyses,6 7 our study is both
long term and UK specific.
CLINICAL DATA
We obtained patient level data from the Treatment of AMD
with PDT (TAP) clinical trial.5 The TAP trial included 609
patients presenting with AMD subfoveal CNV lesions having
a greatest linear dimension of (5400 mm, some evidence of
classic CNV, and best corrected visual acuity between 20/40
and 20/200. One eye from each patient was randomised, 402
to treatment and 207 to placebo. At each 3 month follow up
visit, patients were retreated with the baseline regimen if
fluorescein leakage from CNV was identified on angiography.
The primary study outcome was moderate vision loss (of
the enrolled eye), defined as loss of less than three lines of
visual acuity (15 letters). Of those patients treated with
verteporfin, 53% lost less than three lines of vision compared
to 38% of placebo treated eyes (p,0.001). A total of 82% of
those on verteporfin and 70% on placebo (p,0.001) did not
experience severe vision loss (defined as a loss of less than six
lines, or less than 30 letters).
Prospectively planned subgroup analysis showed similar
visual outcomes (loss of less than 15 letters at 24 months) for
placebo and PDT in patients with minimally classic lesions
(48% for verteporfin patients versus 44% of the placebo
patients), but patients with predominantly classic lesions
given PDT had lower vision loss (59% of those on verteporfin
versus 31% of those on placebo).
Since the approved labelling and current recommendation
for use of verteporfin in the United Kingdom indicate that
only those with predominantly classic CNV should be treated,
this analysis focuses on the subset of 243 patients with that
particular form of disease.
MODELLING THE BENEFITS OF PDT WITH
VERTEPORFIN
We used a Markov model to estimate cost effectiveness for
two time periods—2 years (equivalent to a within trial
estimate) and 5 years. Five years represents a time frame
over which decision making bodies might project and
Abbreviations: AMD, age related macular degeneration; CNV,
choroidal neovascularisation; PDT, photodynamic therapy; QALY,
quality adjusted life year; VA, visual acuity
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minimises the assumptions associated with lengthier extra-
polation. The health states used in the Markov model came
directly from clinical trial visual acuity measurements and
ranged from 20/40 to worse than 20/800, plus the dead state.
Survival analysis with a Weibull function estimated daily
transition probabilities of moving to a lower state of visual
acuity, controlling for baseline visual acuity, sex, and age.
Since there were 15 levels of visual acuity possible in the trial,
a person starting at the best level of acuity would need to
experience 14 Snellen ‘‘drops’’ to reach the worst level of
acuity in the trial. The predicted hazard was then used to
calculate the probability of progression for verteporfin and
placebo, and the uncertainty estimates were used to estimate
the distribution in our probabilistic sensitivity analysis. The
survival function from this hazard can be written as:
exp(2(lt)a)
where l is the Weibull scale parameter, modelled as a log
linear function of the regressors (that is, l=exp(2bx)), and
a is the Weibull shape parameter, which determines whether
the hazard increases or decreases with time. The time
component (t) was varied to produce daily estimates of the
transition probability to a lower level of visual acuity.
Visual acuity was measured every 3 months in the trial, so
linear interpolation estimated the day when a person dropped
more than one line of vision between 3 month clinic visits.
Data Pro (release 6) was used to build the Markov model;
we incorporated probability distributions to generate cost
effectiveness acceptability curves. This model is based on a
cohort of men aged 75 years at the start of therapy.
OUTCOME MEASURES
Vision years were calculated based on time spent with visual
acuity of 20/200 or better, as has been used in previous
studies; this represents ‘‘legal blindness’’ in many countries,
including the United Kingdom.
Health state preference values were taken from a time
trade-off study of 80 patients with AMD.6 These utilities were
20/20–20/25, 0.89 (95% CI, 0.82 to 0.96), 20/30–20/50, 0.81
(95% CI, 0.73 to 0.89), 20/60–20/100, 0.57 (95% CI, 0.47 to
0.67), 20/200–20/400, 0.52 (95% CI, 0.38 to 0.66), and the
ability to count fingers to light perception, 0.40 (95% CI, 0.29
to 0.50). The uncertainty in the utility estimates was
incorporated into the probabilistic sensitivity analysis.
All side effects, with the exception of allergic reactions,
were more prominent in the verteporfin arm.5 We incorpo-
rated the effect of these adverse events through changes in
quality of life, using values from a previous cost effectiveness
analysis on PDT.8 To the extent that these adverse events
cause decreases in vision, their costs are included. We
considered costs of other adverse events to be trivial.
Costs and benefits were discounted at a rate of 6% for costs
and 2% for benefits following recommendations from the UK
Treasury.9
MODEL CALIBRATION
The model predicts gains in vision years based on baseline
visual acuity level. To compare the model predictions to the
actual data, we used an average of the model predictions,
weighted by the proportion of people in the trial at each
visual acuity level; transition to the death state was not
allowed, and the results were undiscounted. The clinical trial
showed a vision year gain of about 0.39 years. The model
predicted a gain of 0.34 years over the 2 year period, or 87%
of the actual gain. Therefore, the model appears to produce
conservative but comparable estimates to the clinical trial.10
COSTS
We present cost estimates from two perspectives, one
considering only the NHS treatment costs (treatment cost
only), and one similar to the National Institute for Clinical
Excellence’s (NICE) recommendation that NHS and personal
social services costs should be considered (government
perspective). The cost estimates in the model are taken from
NICE’s technology assessment report on PDT with vertepor-
fin7 which includes estimates from published national
sources (for example, the British National Formulary, NHS
Reference Costs, Personal Social Services Research Unit Costs
of Health and Social Care), primary literature, and some
primary data collection. All costs have been inflated to
December 2000 prices and reflect the proportion of people
who would experience the cost in a given year. The estimate
of treatment cost only (£1181) includes the cost of
verteporfin and disposables (£860), laser (£101), angiography
(£108), and outpatient appointment (£112).
Because PDT with verteporfin may diminish the rate at
which individuals become blind (that is, 20/200), the
government perspective incorporates possible cost offsets in
medical and social care. The total base case government cost
(exclusive of treatment cost) was estimated at £6295 per year
(range £1325 to £16 800), plus a one-off cost of £159 (range
£50 to £300) for blindness registration, low vision aids, and
rehabilitation services. The annual government costs also
include housing and council tax benefit (£1221), social
security (£1212), tax allowance (£16), depression treatment
(£151), hip replacement (£183), community care (£171), and
residential care (£3340). Our conservative approach uses the
base case (£6295/year) and a sensitivity analysis on the
lower limit of the range (£1325/year) for the government
perspective.
ASSUMPTIONS IN THE ANALYSIS
Re-treatments
Patient follow up is suggested at 3 month intervals for those
receiving PDT with verteporfin treatment. In the clinical trial,
all patients in the verteporfin treated group received follow
up treatment if there was evidence of CNV leakage on
fluorescein angiography. To estimate the number of re-
treatments after the trial, we used a linear trend based on
2 year clinical trial data to predict an average of 1.52 re-
treatments per person from year 2 to 3 and none thereafter.
Table 1 Survival analysis regression results
Parameter DF Estimate SE 95% CL x2 Pr x2
Intercept 1 3.7905 0.3759 3.0536 to 4.5273 101.66 ,0.0001
Sex (1 if male) 1 20.1769 0.1838 20.5372 to 0.1834 0.93 0.336
Baseline Snellen* 1 0.1184 0.0435 0.0331 to 0.2037 7.4 0.0065
Previous treatment (Y/N) 1 20.13 0.1962 20.5146 to 0.2547 0.44 0.5078
Treatment group (1 if verteporfin) 1 0.5109 0.1926 0.1334 to 0.8885 7.04 0.008
Scale 1 1.3366 0.0678 1.2101 to 1.4762
Weibull shape 1 0.7482 0.0379 0.6774 to 0.8264
*Baseline Snellen follows the categories described in the text. DF = degrees of freedom, CL = confidence limits, Pr = probability.
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This correlates well with the 3 year open label extension
analysis.11 Further, we assumed that re-treatment was
independent of baseline visual acuity.
Follow up visits
This analysis assumed that once re-treatments were com-
pleted there would be no further follow up visits for those in
the PDT treatment arm. The costs of follow up angiogram and
outpatient visits are the subject of a sensitivity analysis.
Routine angiograms and visits not related to PDT treatment
are assumed to be used at the same rate in both arms.
Treated eye
A critical assumption in the model is that the better seeing
eye is the treated eye. Since AMD is a progressive, bilateral
disease, the better seeing eye will normally be the second eye
involved.
This issue has generated considerable debate during the
time that PDT has been subject to appraisal by NICE. Visual
function and quality of vision are more strongly correlated
with visual acuity in the better seeing eye than in the poorer
seeing eye,12 suggesting that quality of life is more dependent
on the better seeing eye. Given the budgetary impact of the
widespread use of PDT, this analysis considers a scenario
based on treatment of the better seeing eye.
Treatment alternative
In the 12 month results from TAP, 92% of the patients
eligible for PDT with verteporfin therapy would not have
been eligible for treatment with laser photocoagulation, since
they had subfoveal CNV.13 The proposed guidelines for
clinical use of PDT suggest treatment of a similar patient
population.
Improvements in vision
Even though the clinical trial showed some improvement in
visual acuity associated with verteporfin treatment, the
Markov process used here conservatively did not allow for
improvement in vision. People stayed at their given level of
acuity until their visual acuity worsened. Mortality data for
the model were based on the UK population death rates.
Sensitivity analysis
Results are shown for cohorts with starting visual acuity of
20/40 or 20/100 (average starting visual acuity in the TAP
trial). Results are also shown with and without NHS and
Table 2 Cost effectiveness (CE): government perspective
2 year time frame, cohort with baseline best corrected visual acuity = 20/40
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 1275 6490 5215
Vision years 1.618 1.773 0.155 33 645
QALYs 1.136 1.205 0.069 75 580
2 year time frame, cohort with baseline best corrected visual acuity = 20/100
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 4590 8878 4288
Vision years 1.074 1.383 0.309 13 877
QALYs 0.980 0.995 0.015 285 867
5 year time frame, cohort with baseline best corrected visual acuity = 20/40
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 10 200 11 700 1500
Vision years 2.160 3.050 0.890 1685
QALYs 2.205 2.375 0.170 8823
5 year time frame, cohort with baseline best corrected visual acuity = 20/100
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 15,700 18,500 2,800
Vision years 1.222 1.858 0.636 4,402
QALYs 1.999 2.093 0.094 29,787
Figure 1 Cost effectiveness acceptability curve on cost per QALY.
(A) Treatment cost only, (B) governmental perspective.
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social care costs. We reduced cost offsets from the govern-
ment perspective to the low end of the range, and
investigated changing assumptions regarding angiographic
follow up of those treated with PDT was investigated. We also
undertook a probabilistic sensitivity analysis, displayed as a
cost effectiveness acceptability curve, wherein we varied
transition probabilities and health state utilities assuming a
normal distribution.
SURVIVAL ANALYSIS RESULTS
Table 1 shows results of the survival analysis upon which the
Markov transition probabilities were based. The regression
shown here is for a drop of one Snellen visual acuity state. In
the Markov model, transitioning from one state of visual
health to the next worse state (that is, one Snellen drop)
depends on one’s baseline visual acuity and values of the
other covariates in the model from the regression shown.
MARKOV MODEL RESULTS
Tables 2 and 3 show the results of the cost effectiveness
analyses. Two sets of results are shown in each table, one for
a cohort with a starting visual acuity of 20/40 and one
starting at 20/100. This range represents both the best and
average visual acuity from the trial. Table 2 shows cost
effectiveness ratios from the government perspective, and
table 3 shows results when only treatment costs are included.
From the government perspective, over the 2 year period,
the expected incremental cost effectiveness ratios range
from £286 000 (starting VA 20/100) to £76 000 (starting VA
20/40) per QALY gained and from £14 000 (20/100) to
Table 3 Cost effectiveness (CE): PDT treatment cost only
2 year time frame, cohort with baseline best corrected visual acuity = 20/40
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 0 6173 6173
Vision years 1.618 1.773 0.155 39 826
QALYs 1.136 1.205 0.069 89 464
2 year time frame, cohort with baseline best corrected visual acuity = 20/100
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 0 6173 6173
Vision years 1.074 1.383 0.309 19 977
QALYs 0.980 0.995 0.015 411 533
5 year time frame, cohort with baseline best corrected visual acuity = 20/40
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 0 6475 6475
Vision years 2.160 3.050 0.890 7275
QALYs 2.205 2.375 0.170 38 088
5 year time frame, cohort with baseline best corrected visual acuity = 20/100
Placebo Verteporfin Difference CE ratio
Cost (£ sterling) 0 6475 6475
Vision years 1.222 1.858 0.636 10 180
QALYs 1.999 2.093 0.094 68 882
Table 4 Sensitivity analysis
Cost per QALY, 5 year time frame, cohort with best corrected visual acuity = 20/40 (in £000)
Values
Government
perspective PDT cost only
Base case 9 38
Government perspective,
low estimate
£1325/year 32 NA
Angiogram follow up* £2640 (angiogram+outpatient visit every
3 months after PDT treatment ends)
24 54
Cost per QALY, 5 year time frame, cohort with best corrected visual acuity = 20/100 (in £000)
Values
Government
perspective PDT cost only
Base case 30 69
Government perspective,
low estimate
£1325/year 61 NA
Angiogram follow up* £2640 (angiogram+outpatient visit every
3 months after PDT treatment ends)
58 97
*In the base case, it is assumed that an angiogram is used for follow up only during the course of treatment. This
sensitivity analysis assumes PDT treated patients have an angiogram and outpatient visit every 3 months for the
entire period of the model for follow up, regardless of whether or not PDT is being given. This is in addition to
standard follow up being done for non-PDT treated patients.
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£34 000 (20/40) per vision year gained. A 5 year perspective
yields incremental ratios less than £5000 for vision years
gained and from £9000 (20/40) to £30 000 (20/100) for
QALYs gained. Without societal or NHS cost offsets included,
the 2 year incremental cost per vision year gained ranges
from £20 000 (20/100) to £40 000 (20/40), and the 2 year
incremental cost per QALY gained ranges from £412 000
(20/100) to £90 000 (20/40). The 5 year time frame shows
expected costs of £7000 (20/40) to £10 000 (20/100) per
vision year gained and from £38 000 (20/40) to £69 000
(20/100) per QALY gained.
Table 4 shows the results of several sensitivity analyses on
two cohorts followed for 5 years, one with a starting visual
acuity of 20/40 and one with a starting visual acuity of
20/100. Using the low estimate of the government perspective
costs increases the cost effectiveness ratio by about threefold
(from £9000 per QALY gained to £32 000 for the 20/40 cohort,
and from £30 000 per QALY to £89 000 for the 20/100
cohort). Changing the assumption of follow up so that PDT
treated patients receive an angiogram every 3 months (even
after treatment with PDT ends), increases the cost per QALY
gained by about £15 000 for those starting at 20/40 and about
£30 000 for those starting at 20/100.
Figure 1 shows the cost effectiveness acceptability curve
(CEAC) at 5 years for cohorts beginning treatment at 20/40
and at 20/100, from the government perspective and
considering cost of treatment only. The CEACs shown here
are a graphical display of the probability of a therapy being
cost effective at a given level of willingness to pay for a QALY.
For example, at a willingness to pay of £30 000 or less, PDT is
cost effective for those starting treatment at 20/40 less than
30% of the time under the treatment cost only scenario, but
almost 80% under the government perspective. At the same
willingness to pay, PDT is cost effective for those starting
treatment at 20/100 less than 5% of the time under the
treatment cost only scenario, and about 45% of the time from
the government perspective.
DISCUSSION
Our modelling suggests that, in terms of QALY gains, treating
predominantly classic, subfoveal AMD lesions using PDT
with verteporfin has a better chance to be cost effective when
initiated at better levels of visual acuity. The estimated
incremental gain in vision years from treatment is smaller
when initiated at a higher level of baseline visual function.
The differing results for the two outcomes reflect the non-
linear nature of the estimated function of vision loss and
illustrate how the two outcomes differentially weight the
time spent in a given vision state. The anticipated treatment
value for money becomes greater as follow up increases and
more cost offsets are included in the analysis. An examina-
tion of tables 2 and 3 shows that over the short term
(2 years), there is little difference in the results between a
government perspective or considering treatment costs only,
but the two perspectives show a much larger proportional
difference at 5 years.
Since PDT therapy may be more cost effective in patients
with better visual acuity (and therefore, at an earlier stage of
disease), screening those at risk may be a practical method of
deploying this technology. Additional work would be needed
to quantify the efficiency of such an approach.
Anecdotal evidence suggests that clinicians are treating
patients with fewer courses of therapy than in the TAP trial
(that is, 2–3 versus 5–6). To the extent that this is the case,
the cost effectiveness ratios produced by our model will be
approximately halved, assuming that similar outcomes are
observed. Further study should determine whether similar
outcomes would accrue with fewer treatments.
These results are applicable only where the treated eye is
the better seeing eye and has subfoveal, predominantly
classic CNV. If the worse seeing eye (often the first eye
involved with AMD) is treated, the results shown here are
probably too optimistic. Further, if the treatment is used
outside the context of those with predominantly classic,
subfoveal CNV, these results would not apply.
The base case gains predicted by the model come largely
from extending the time horizon beyond the trial period. The
additional data from follow up of the trial’s PDT arm suggests
that there is clinical benefit beyond 2 years, so modelling this
potential gain is relevant and useful.
The results here are sensitive to several of the assumptions.
Incorporation of social care costs is clearly significant, as is
the time frame over which benefits are modelled and the
starting visual acuity. Additionally, the assumptions regard-
ing follow up treatment are important, almost tripling the
cost per QALY estimate for the treatment cost only
perspective. These factors must be considered carefully in
policy decisions about PDT’s place in therapy.
A limitation of this work is that the primary outcome
measure used, visual acuity as measured by the Snellen score,
may not adequately capture the full known effects of PDT.
For example, PDT has been shown to benefit contrast
sensitivity,5 and contrast sensitivity correlates well with
visual function.12 However, visual acuity also correlates very
well with visual function12 14 and has a clinical appeal as an
overall measure of visual function and quality of life.
There are now open label follow up data for up to 4 years
on 58% of the TAP trial treatment arm.15 These data are not
placebo controlled, and not all patients in the original study
entered the extension phase; it only included patients for
whom continued PDT might reduce further vision loss. These
data may represent a biased sample of patients who would be
treated with PDT, and should thus be interpreted with
caution. These data show a loss of three lines of vision in 36%
of patients at 24 months, 41% at 36 months, and 43% at
48 months. It may be that these data are indicative of either a
stabilisation or increased slowing in vision loss—which
would imply that our model is too conservative, because
the model’s treated arm experiences a continued decline in
visual function. Alternatively, it may be the result of the
natural disease process, implying that our model produces
results biased towards PDT. Further follow up using an
intention to treat design would be beneficial to clinicians and
policy makers.
We based our model on a prospectively planned subgroup
analysis from the TAP trial. Because it was a subgroup and
not the entire population treated, these results only apply in a
situation where those treated have predominantly classic
disease—it should be clearly noted that patients without
predominantly classic disease in the TAP population did not
fare as well with verteporfin treatment. One additional
criticism is the possibility that the clinical effects found in
the subgroup are solely the result of chance. We chose this
subgroup because it is the patient population and data upon
which regulatory agencies have based the drug’s licensure.
CONCLUSION
This analysis focuses on only those with a particular form of
exudative AMD (predominantly classic, subfoveal CNV). Our
evaluation suggests that early treatment (that is, treating
eyes at less severe stages of disease) with PDT leads to
increased efficiency. When considering only the cost of
therapy, treating people at lower levels of visual acuity would
probably not be considered cost effective. However, a broad
perspective that incorporates other NHS treatment costs and
social care costs suggests that over a long period of time, PDT
may yield reasonable value for money. Consideration should
Cost effectiveness of PDT with verteporfin for AMD 1111
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be given to early detection and treatment, particularly in the
second eye to become involved. Further study aimed at
potential screening may yield clues to an optimal use of PDT.
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